NASDAQ:ACGN Aceragen (ACGN) Stock Price, News & Analysis → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free ACGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.38▼$0.3850-Day Range$0.38▼$0.9052-Week Range$0.36▼$16.00VolumeN/AAverage VolumeN/AMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aceragen alerts: Email Address Ad Porter & CompanyNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I explain what this Keystone technology is… why it’s so critical to the future of not just AI but mankind… You must read this new presentation from Porter Stansberry. About Aceragen Stock (NASDAQ:ACGN)Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.Read More Ad Porter & CompanyNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I explain what this Keystone technology is… why it’s so critical to the future of not just AI but mankind… You must read this new presentation from Porter Stansberry. ACGN Stock News HeadlinesAugust 26, 2023 | ca.finance.yahoo.comACGN - Aceragen, Inc.August 8, 2023 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.16%August 4, 2023 | finance.yahoo.comAceragen, Inc. to Delist from The Nasdaq Stock MarketJuly 12, 2023 | bizjournals.comCash-strapped public company in Durham moves to liquidate. Will shareholders get anything?July 11, 2023 | bizjournals.comInvestor wants its money back as Durham firm weighs bankruptcyJune 29, 2023 | chron.comAceragen: Q1 Earnings SnapshotMay 30, 2023 | finance.yahoo.comAceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingApril 17, 2023 | bizjournals.comDurham public company begins furloughs as it searches for capitalMarch 30, 2023 | benzinga.comAceragen Stock (NASDAQ:ACGN), Guidance and ForecastMarch 5, 2023 | barrons.comAceragen Inc.March 1, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Aceragen (ACGN)February 6, 2023 | finance.yahoo.comAceragen Announces Recommendation of Data Monitoring Committee in Terra StudySee More Headlines Receive ACGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aceragen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/10/2024Next Earnings (Estimated)7/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACGN CUSIPN/A CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$4.86 million Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.12Miscellaneous Outstanding Shares8,420,000Free Float6,196,000Market Cap$3.20 million OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. John C. Taylor (Age 52)Pres, CEO & Director Comp: $444.06kMs. Gwen ThomasAssociate Director of HR, Fin. & Admin.Ms. Christina AmendolaDirector of HRMr. Brian JackeySr. VP of Technical OperationsMs. Deepa NagpalGlobal Head of QualityDr. Shah Rahimian M.D.Ph.D., Medical Director & Global Clinical Lead for OncologyDr. Joanna Caroline Horobin Ch.B (Age 68)M.B., Advisor Mr. Louis J. Arcudi III (Age 62)M.B.A., MBA, Adviser More ExecutivesKey CompetitorsAlvotechNASDAQ:ALVOEntera BioNASDAQ:ENTXGenocea BiosciencesNASDAQ:GNCAQVectivBioNASDAQ:VECTOncoSec MedicalNASDAQ:ONCSView All CompetitorsInsidersMaxine GowenSold 51 sharesTotal: $26.01 ($0.51/share)Invest Corp PillarSold 3,605 sharesTotal: $5,695.90 ($1.58/share) ACGN Stock Analysis - Frequently Asked Questions When is Aceragen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ACGN earnings forecast. This page (NASDAQ:ACGN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aceragen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aceragen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.